Core Viewpoint - Structure Therapeutics Inc. has initiated a first-in-human Phase 1 clinical study of ACCG-2671, an oral small molecule amylin receptor agonist aimed at treating obesity, marking a significant milestone in the company's development pipeline [1][3]. Company Overview - Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral small molecule treatments for chronic metabolic conditions, particularly obesity, utilizing a next-generation structure-based drug discovery platform [7]. Product Development - ACCG-2671 is designed to leverage the metabolic benefits of amylin biology, offering a once-daily dosing regimen that enhances scalability, combinability, and patient access [1][2]. - The Phase 1 study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of ACCG-2671 in both healthy volunteers and individuals with obesity, including single-ascending and multiple-ascending dose cohorts [2]. Clinical Data and Pipeline - Preclinical data indicate that ACCG-2671 demonstrates potent target engagement and significant weight loss both as a monotherapy and in combination with GLP-1 receptor agonists, alongside a favorable safety and pharmacokinetics profile [2][4]. - The company is also advancing ACCG-3535, a second dual amylin and calcitonin receptor agonist (DACRA), and is developing selective amylin receptor agonists (SARAs) currently in preclinical stages [6]. Market Position - The company believes that amylin-based therapies will become a crucial next-generation component in the treatment landscape for obesity and related conditions, highlighting the potential of ACCG-2671 as a differentiated backbone therapy [2][3].